DF Dent & Co. Inc. Has $20.77 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

DF Dent & Co. Inc. trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 112,530 shares of the medical research company’s stock after selling 7,515 shares during the period. DF Dent & Co. Inc. owned about 0.22% of Charles River Laboratories International worth $20,773,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRL. Cerity Partners LLC increased its position in Charles River Laboratories International by 65.9% in the third quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company’s stock worth $963,000 after purchasing an additional 1,943 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Charles River Laboratories International by 9.5% during the third quarter. Glenmede Trust Co. NA now owns 1,210 shares of the medical research company’s stock worth $238,000 after buying an additional 105 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Charles River Laboratories International by 4.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,812 shares of the medical research company’s stock valued at $1,933,000 after buying an additional 423 shares during the period. Public Sector Pension Investment Board boosted its stake in Charles River Laboratories International by 15.1% in the third quarter. Public Sector Pension Investment Board now owns 2,282 shares of the medical research company’s stock valued at $449,000 after acquiring an additional 300 shares during the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of Charles River Laboratories International by 256.5% during the 3rd quarter. Benjamin Edwards Inc. now owns 1,451 shares of the medical research company’s stock valued at $286,000 after acquiring an additional 1,044 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, COO Birgit Girshick acquired 1,514 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL opened at $149.30 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $142.76 and a twelve month high of $264.71. The stock has a market capitalization of $7.63 billion, a P/E ratio of 995.33, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a 50 day moving average of $163.57 and a 200-day moving average of $181.69.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the business earned $2.46 EPS. The company’s revenue was down 1.1% compared to the same quarter last year. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of analyst reports. Barclays decreased their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 18th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $189.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).